Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Supercharged immune cells take on childhood cancers in new trial

NCT ID NCT03721068

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 28 times

Summary

This early-phase study tests a new treatment for children whose neuroblastoma or osteosarcoma has returned or not responded to standard therapy. The treatment uses the patient's own immune T-cells, modified in a lab to better recognize and attack cancer cells that carry a marker called GD2. The main goals are to check the treatment's safety and find the best dose, not yet to prove it can cure the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Emory - Winship Cancer Institute

    WITHDRAWN

    Atlanta, Georgia, 30322, United States

  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

    RECRUITING

    Chapel Hill, North Carolina, 27599-7295, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.